CYP2B6 and posterior cortical atrophy: Later, we combined CYP1A1, CYP2B6, CYP3A4, UGT1A8, UGT2B11, UGT2B17, UGT2B7, GAS5, XIST, SNHG6, which showed good correlations to chemotherapy or endocrine therapy resistance, to predict drug response and treatment outcomes in 69 PCa patients who have previously received chemotherapy or endocrine therapy.